Schweizerischer Nationalfonds / Fonds national suisse
Storys zum Thema Mutation
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
REVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY
Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
What triggers photoreceptor cell death in a disease leading to blindness?
Bern (ots) - In the common eye disease retinitis pigmentosa, the rods and cones of the retina slowly die. Single cell analysis provides insights into the onset of this process. First night blindness and tunnel vision, then the loss of contrast and colour and, in the worst case, total blindness: this is the typical course of retinitis pigmentosa, a hereditary disease of ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Speeding up genetic diagnosis of Huntington's disease
Bern (ots) - Elongated segments of DNA cause Huntington's disease and certain other disorders of the brain. Researchers funded by the SNSF have developed a method to determine the length of the mutated genes quickly and easily. People with Huntington's disease suffer from jerky body movements and decreasing mental abilities. The condition usually leads to death 15-20 years after diagnosis. The cause of the disease is a ...
mehrMerck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...
mehr